CG Oncology Past Earnings Performance
Past criteria checks 0/6
CG Oncology's earnings have been declining at an average annual rate of -40%, while the Biotechs industry saw earnings growing at 19.3% annually. Revenues have been declining at an average rate of 160.2% per year.
Key information
-40.0%
Earnings growth rate
6.9%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | -160.2% |
| Return on equity | -13.6% |
| Net Margin | -11,510.4% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
CG Oncology: Positive Phase 3 Outcome Could Lead To BLA Of Cretostimogene
Dec 13Companies Like CG Oncology (NASDAQ:CGON) Are In A Position To Invest In Growth
Oct 04
CG Oncology: Promising Data, But Looks Expensive
Aug 26CG Oncology, Inc. (NASDAQ:CGON) Shares Could Be 42% Below Their Intrinsic Value Estimate
Jul 25CG Oncology Bringing Undervalued Innovation To Bladder Cancer
Jul 09CG Oncology: ASCO Play And Top-Line Data End Of 2024 Could Drive Further Value
May 06Revenue & Expenses Breakdown
How CG Oncology makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 1 | -79 | 25 | 0 |
| 31 Mar 24 | 1 | -72 | 14 | 0 |
| 31 Dec 23 | 0 | -68 | 10 | 0 |
| 30 Sep 23 | 0 | -57 | 9 | 0 |
| 31 Dec 22 | 0 | -44 | 6 | 0 |
| 31 Dec 21 | 10 | -18 | 5 | 0 |
Quality Earnings: CGON is currently unprofitable.
Growing Profit Margin: CGON is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if CGON's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare CGON's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CGON is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.6%).
Return on Equity
High ROE: CGON has a negative Return on Equity (-13.56%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/27 00:59 |
| End of Day Share Price | 2024/12/27 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
CG Oncology, Inc. is covered by 6 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Charlie Yang | BofA Global Research |
| Joshua Schimmer | Cantor Fitzgerald & Co. |
| Corinne Johnson | Goldman Sachs |